Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 4/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 7/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.37 |
| ▸ | TDP2 | O95551 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | HPGDS | O60760 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3961115 | 0.80 | CYP11B1 (0.41) | CHRNB2CHRNA4CYP11B1CYP11B2CHRNA3 | |
| SCHEMBL3969133 | 0.78 | PDK2 (0.39) | DRD2CYP11B1CYP11B2CYP1A2TDP2 | |
| SCHEMBL13627451 | 0.77 | CHRM2 (0.32) | — | |
| SCHEMBL3966221 | 0.77 | CHRM2 (0.32) | — | |
| SCHEMBL3966537 | 0.77 | SLC6A2 (0.38) | CYP3A4 | |
| SCHEMBL3969125 | 0.75 | DRD2 (0.38) | DRD2 | |
| SCHEMBL17489925 | 0.75 | CYP11B1 (0.46) | DRD2CYP11B1CYP11B2CYP1A2TDP2 | |
| SCHEMBL3965155 | 0.74 | SLC6A2 (0.36) | DRD2PDK2 | |
| SCHEMBL17489921 | 0.71 | CYP11B1 (0.38) | DRD2CYP11B1CYP11B2CYP1A2TDP2 | |
| SCHEMBL3167913 | 0.71 | CYP11B2 (0.41) | CHRNB2CHRNA4DRD2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| EP-1910353-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007030089-A1 | TRICYCLIC DELTA- OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-03-15 | — | — | WO | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRM1 | CHRNB2 208/4885CHRNA4 104/4885DRD2 49/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CHRNB2 116/4885CHRNA4 34/4885DRD2 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.